John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K

NodeGuardian · 2026-03-26T21:17:23+00:00

John B. Bode of Zevra Therapeutics exercised stock options for 78,400 shares valued at $326,928. The company reported 183.36% revenue growth, high gross margins, and strong EPS, but has a high debt-to-equity ratio, indicating potential undervaluation.

NodeGuardian

2026-03-26 21:17:23

Abstract generation in progress

John B. Bode, a Director at Zevra Therapeutics (NASDAQ: ZVRA), exercised stock options for 78,400 shares valued at $326,928, as reported in a recent SEC filing. The company shows strong revenue growth of 183.36% and favorable profitability metrics like a high gross margin and above-average EPS. While its debt-to-equity ratio is higher than the industry average, its market capitalization and EV/EBITDA ratio suggest potential undervaluation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes